Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Moore, Malcolm J., Goldstein, David, Hamm, John, Figer, Arie, Hecht, Joel R., Gallinger, Steven, Au, Heather J., Murawa, Pawel +9 more·2007·Journal of Clinical Oncology

DOI 10.1200/jco.2006.07.9525

Cited by (1,008)

Items 401–500 of 1,008

Persistent activation of pancreatic stellate cells creates a microenvironment favorable for the malignant behavior of pancreatic ductal adenocarcinoma
Dong Tang, Daorong Wang, Zhongxu Yuan, Xiaofeng Xue, Ye Zhang, Yong An, Jian‐Min Chen, Min Tu, Zipeng Lu, Jishu Wei et al. · 2012 · International Journal of Cancer
A Phase II Study of Fixed-Dose Rate Gemcitabine Plus Low-Dose Cisplatin Followed by Consolidative Chemoradiation for Locally Advanced Pancreatic Cancer
Andrew H. Ko, Jeanne Marie Quivey, Alan Paul Venook, Emily K. Bergsland, Elizabeth Dito, Brian Schillinger, Margaret A. Tempero · 2007 · International Journal of Radiation Oncology*Biology*Physics
State of the art and future directions of pancreatic ductal adenocarcinoma therapy
Cindy Neuzillet, Annemilaï Tijeras‐Raballand, Philippe Bourget, Jerome F. Cros, Anne Couvelard, Alain Sauvanet, Marie‐Pierre Vullierme, Christophe Tournigand, Pascal R. Hammel · 2015 · Pharmacology & Therapeutics
Mechanisms of tumor resistance to EGFR-targeted therapies
Elizabeth A. Hopper-Borge, Rochelle E. Nasto, Vladimir Ratushny, Louis M. Weiner, Erica A. Golemis, Igor A. Astsaturov · 2009 · Expert Opinion on Therapeutic Targets
OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer
Virginie Baylot, Claudia Andrieu, Maria Katsogiannou, David Taïeb, Stéphane Garcia, Sophie Giusiano, Julie Acunzo, Juan Iovanna, Martin Edwin Gleave, Carmen Garrido et al. · 2011 · Cell Death and Disease
Reporting of Serious Adverse Drug Reactions of Targeted Anticancer Agents in Pivotal Phase III Clinical Trials
Boštjan Šeruga, Lynn Sterling, Lisa E. Wang, Ian F. Tannock · 2010 · Journal of Clinical Oncology
Characterization of soluble and exosomal forms of the EGFR released from pancreatic cancer cells
Kamila A. Adamczyk, Susanne Klein‐Scory, Mahnaz Moradian Tehrani, Uwe H. Warnken, Wolff Schmiegel, Martina Schnölzer, Irmgard Schwarte‐Waldhoff · 2011 · Life Sciences
Elevated COX-2 Expression Promotes Angiogenesis Through EGFR/p38-MAPK/Sp1-Dependent Signalling in Pancreatic Cancer
Hai Xia Hu, Ting Han, Meng Zhuo, Leilei Wu, Cuncun Yuan, Lixia Wu, Lei Wang, Feng Jiao, Liwei Wang · 2017 · Scientific Reports
Why HALO 301 Failed and Implications for Treatment of Pancreatic Cancer
Nausheen Hakim, Rajvi Patel, Craig Devoe, Muhammad Wasif Saif · 2019 · Pancreas - Open Journal
Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review
Tomas Koltai, Stephan J. Reshkin, Tiago M. A. Carvalho, Daria Di Molfetta, Maria Raffaella Greco, Khalid Omer Alfarouk, Rosa Angela Cardone · 2022 · Cancers
Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial
Matthias J. Löhr, Stephan Haas, Wolf O. Bechstein, Gyorgy Bodoky, Karel Cwiertka, Wolfgang Fischbach, Ulrich Robert Fölsch, Dirk Jäger, D. Osinsky, Jana Prausová et al. · 2011 · Annals of Oncology
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium
Kindler, Hedy Lee, Wroblewski, Kristen, Wallace, James A., Hall, Michael J., Locker, Gershon, Nattam, Sreenivasa, Agamah, Edem, Stadler, Walter M., Vokes, Everett E. · 2012 · Investigational New Drugs
Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer
Daniel A. Laheru, Preeti Shah, N.V. Rajeshkumar, Florencia M. McAllister, Gretchen Taylor, Howard G. Goldsweig, Dung Thi Le, Ross C. Donehower, Antonio Jimeno, Sheila Linden et al. · 2012 · Investigational New Drugs
ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?
Aleksandra Adamska, Marco Falasca · 2018 · World Journal of Gastroenterology
Rash as a Surrogate Marker for Efficacy of Epidermal Growth Factor Receptor Inhibitors in Lung Cancer
Roman Perez-Soler · 2006 · Clinical Lung Cancer
Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trial—SAKK 44/00–CECOG/PAN.1.3.001
Jürg Bernhard, Daniel Dietrich, Werner Scheithauer, Daniela Gerber, Gyorgy Bodoky, Thomas Ruhstaller, Bengt L. G. Glimelius, Emilio Bajetta, Johann Schueller, Piercarlo Saletti et al. · 2008 · Journal of Clinical Oncology
A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study
Yousuke Nakai, Hiroyuki Isayama, Takashi Sasaki, Naoki Sasahira, Takuya Tsujino, Nobuo Toda, Hirofumi Kogure, Saburo Matsubara, Yukiko Ito, Osamu Togawa et al. · 2012 · British Journal of Cancer
Mechanisms of Disease: chronic inflammation and cancer in the pancreas—a potential role for pancreatic stellate cells?
Hana Algül, Matthias Treiber, Marina Lesina, Roland Michael Schmid · 2007 · Nature Clinical Practice Gastroenterology &#38 Hepatology
Myeloid-Derived Suppressor Cells: General Characteristics and Relevance to Clinical Management of Pancreatic Cancer
Peter S. Goedegebuure, Jonathan B. Mitchem, Matthew R. Porembka, Marcus Chuan Beng Tan, Brian A. Belt, Andrea Wang‐Gillam, William E. Gillanders, William G. Hawkins, David C. Linehan · 2011 · Current Cancer Drug Targets
Cancer: The Road to Amiens
David J. Stewart, Razelle Kurzrock · 2008 · Journal of Clinical Oncology
The acinar regulator Gata6 suppresses KrasG12V-driven pancreatic tumorigenesis in mice
P. Martinelli, Francesc Madriles, M. Cañamero, E. Pau, Natalia Del Pozo, C. Guerra, F. Real · 2015 · Gut
Axitinib—a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor
Ronan Joseph Kelly, Olivier Rixe · 2009 · Targeted Oncology
Metastatic Pancreatic Cancer 2008: Is the Glass Less Empty?
Jacqueline Nieto, Michael L. Grossbard, Peter S. Kozuch · 2008 · The Oncologist
International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer
Kyoichi Takaori, Claudio Bassi, Andrew Victor Biankin, Thomas Baptist Brunner, Ivana Cataldo, Fiona Campbell, David Cunningham, Massimo Falconi, Adam Enver Frampton, Junji Furuse et al. · 2015 · Pancreatology
Pancreatic cancer: Current research and future directions
Marco Falasca, Minkyoung Kim, Ilaria Casari · 2016 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer
Srinivasa P. Pothula, Zhihong Xu, David Goldstein, Andrew Victor Biankin, Romano C. Pirola, Jeremy S. Wilson, Minoti Vivek Apte · 2016 · British Journal of Cancer
The Role of Inflammation in Pancreatic Cancer
Simone Hausmann, Bo Kong, Christoph W. Michalski, Mert Erkan, Helmut Frieß · 2014 · Advances in experimental medicine and biology
The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer
Thierry Conroy, Céline Gavoille, Emmanuelle Samalin, Marc Ychou, Michel Pierre Ducreux · 2013 · Current Oncology Reports
A Phase II Trial of nab-Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer
Peter J. Hosein, Gilberto De Lima Lopes Jr., Vitor H. Pastorini, Christina Gomez, Jessica MacIntyre, Gloria Zayas, Isildinha Marques dos Reis, Alberto J. Montero, Jaime Rafael Merchan, Caio M. Rocha Lima · 2012 · American Journal of Clinical Oncology
Incremental Advance or Seismic Shift? The Need to Raise the Bar of Efficacy for Drug Approval
Alberto Felice Sobrero, Paolo Bruzzi · 2009 · Journal of Clinical Oncology
Pancreatic cancer microenvironment: a current dilemma
Burak Uzunparmak, İbrahim Halil Şahin · 2019 · Clinical and Translational Medicine
Some essential considerations in the design and conduct of non-inferiority trials
Thomas R. Fleming, Katherine Odem‐Davis, Mark D. Rothmann, Yuan Li Shen · 2011 · Clinical Trials
Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas
Zhiqiang Meng, Christopher R. Garrett, Yijun Shen, L Liu, Peiying Yang, Y Huo, Qi Zhao, Amy R. Spelman, Chaan S. Ng, David Z. Chang et al. · 2012 · British Journal of Cancer
Assessment of Chk1 Phosphorylation as a Pharmacodynamic Biomarker of Chk1 Inhibition
Leslie A. Parsels, Yushen Qian, Daria M. Tanska, Marisa Gross, Lili Zhao, Maria C. Hassan, Sankari Arumugarajah, Joshua D. Parsels, Linda Hylander-Gans, Diane M. Simeone et al. · 2011 · Clinical Cancer Research
Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC)
Sreenivasa Rao Chandana, Hani M. Babiker, Daruka Mahadevan · 2018 · Expert Opinion on Investigational Drugs
Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer
Hitendra Patel, Ryosuke Okamura, Paul Timothy Fanta, Charmi Patel, Richard Burnham Lanman, Victoria M. Raymond, Shumei Kato, Razelle Kurzrock · 2019 · Journal of Hematology & Oncology
3,3′-Diindolylmethane Enhances Chemosensitivity of Multiple Chemotherapeutic Agents in Pancreatic Cancer
Sanjeev Banerjee, Zhiwei Wang, Dejuan Kong, Fazlul H. Sarkar · 2009 · Cancer Research · Retracted
A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
Chigusa Morizane, Takuji Okusaka, Junji Furuse, Hiroshi Ishii, Hideki Ueno, Masafumi Ikeda, Kohei Nakachi, Mina Najima, Takashi Ogura, Eiichiro Suzuki · 2008 · Cancer Chemotherapy and Pharmacology
Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment
Kishore Polireddy, Qi Chen · 2016 · Journal of Cancer
Pulmonary toxicities from targeted therapies: a review
Nicholas A. Barber, Apar Kishor Ganti · 2011 · Targeted Oncology
Molecular landscape of pancreatic cancer: implications for current clinical trials
Gregory M. Heestand, Razelle Kurzrock · 2015 · Oncotarget
Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer
Tetsuhito Muranaka, Masaki Kuwatani, Yoshito Komatsu, Kentaro Sawada, Hiroshi Nakatsumi, Yasuyuki Kawamoto, Satoshi Yuki, Yoshimasa Kubota, Kimitoshi Kubo, Shuhei Kawahata et al. · 2017 · Journal of Gastrointestinal Oncology
Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2)
Guanggai Xia, Hongcheng Wang, Ziliang Song, Qingcai Meng, Xiu−Yan Huang, Xinyu Huang · 2017 · Journal of Experimental & Clinical Cancer Research
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis
Robert Lance Fine, David R. Fogelman, Stephen M. Schreibman, Manisha Desai, William H. Sherman, J.B. Strauss, Susan C. Guba, Riolan Andrade, John A. Chabot · 2007 · Cancer Chemotherapy and Pharmacology
Epigenetics and pancreatic cancer: Pathophysiology and novel treatment aspects
Daniel Neureiter · 2014 · World Journal of Gastroenterology
A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer
G. Deplanque, Martin Demarchi, Mohamed Hebbar, Patrick J. Flynn, Bohuslav Melichar, J. Atkins, Elżbieta Nowara, Lemuel A. Moyé, David Piquemal, D. Ritter et al. · 2015 · Annals of Oncology
Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib
Taiga Otsuka, Yuichiro Eguchi, Seiji Kawazoe, Kimihiko Yanagita, Keisuke Ario, Kenji Kitahara, Hiroaki Kawasoe, Hiroyuki Kato, Toshihiko Mizuta, the Saga Liver Cancer Study Group · 2012 · Hepatology Research
Treatment of advanced pancreatic cancer: From gemcitabine single agent to combinations and targeted therapy
Fernando Rivera, Sara López‐Tarruella, M. E. Vega-Villegas, Matilde Salcedo · 2009 · Cancer Treatment Reviews
Survival Benefit With Proapoptotic Molecular and Pathologic Responses From Dual Targeting of Mammalian Target of Rapamycin and Epidermal Growth Factor Receptor in a Preclinical Model of Pancreatic Neuroendocrine Carcinogenesis
Christopher W. Chiu, Hiroaki Nozawa, Douglas Hanahan · 2010 · Journal of Clinical Oncology
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine
James R. W. Conway, David Herrmann, TR Jeffry Evans, Jennifer P. Morton, Paul Timpson · 2018 · Gut
Consensus, debate, and prospective on pancreatic cancer treatments
Junke Wang, Jie Yang, Amol Kumar Narang, Jing He, Christopher L. Wolfgang, Keyu Li, Lei Zheng · 2024 · Journal of Hematology & Oncology
A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma
Andrea Wang‐Gillam, Stacey M. Plambeck-Suess, Peter S. Goedegebuure, Peter O. Simon, Jonathan B. Mitchem, John R. Hornick, Steven M. Sorscher, Joel Picus, Rama Suresh, Albert Craig Lockhart et al. · 2012 · Investigational New Drugs
Targeting the Ras–ERK pathway in pancreatic adenocarcinoma
Cindy Neuzillet, Pascal R. Hammel, Annemilaï Tijeras‐Raballand, Anne Couvelard, Éric Raymond · 2012 · Cancer and Metastasis Reviews
Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer
Sumiyuki Nishida, Shigeo Koido, Yutaka Takeda, Sadamu Homma, Hideo Komita, Akitaka Takahara, Satoshi Morita, Toshinori Ito, Soyoko Morimoto, Kazuma Hara et al. · 2014 · Journal of Immunotherapy
Randomized phase II / III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS ‐ PC Study
Hiroki Yamaue, Takuya Tsunoda, Masaji Tani, Motoki Miyazawa, Kenji Yamao, Nobumasa Mizuno, Takuji Okusaka, Hideki Ueno, Narikazu Boku, Akira Fukutomi et al. · 2015 · Cancer Science
Dual blockade of epidermal growth factor receptor and insulin‐like growth factor receptor–1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)
Philip A. Philip, Bryan H. Goldman, Ramesh K. Ramanathan, Heinz‐Josef Lenz, Andrew M. Lowy, Robert P. Whitehead, Takeru Wakatsuki, Syma Iqbal, Rakesh Gaur, Jacqueline Benedetti et al. · 2014 · Cancer
Margin status, recurrence pattern, and prognosis after resection of pancreatic cancer
Teiichi Sugiura, Katsuhiko Uesaka, Kisho Mihara, Keiko Sasaki, Hideyuki Kanemoto, Takashi Mizuno, Yukiyasu Okamura · 2013 · Surgery
Economic Analysis of Radiation Therapy Oncology Group 97-14
Andre A. Konski, J. James, William F. Hartsell, Mark H. Leibenhaut, Nora Anita Janjan, Walter Curran, Mack Roach, Deborah Watkins Bruner · 2009 · American Journal of Clinical Oncology
Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?
Axel Schulenburg, Katharina Blatt, Sabine Cerny‐Reiterer, Irina Sadovnik, Harald Herrmann, Brigitte Marian, Thomas W. Grunt, Christoph Carl Zielinski, Peter Valent · 2015 · Journal of Hematology & Oncology
Angiogenin/ribonuclease 5 is an EGFR ligand and a serum biomarker for erlotinib sensitivity in pancreatic cancer
Ying-Nai Wang, Heng-Huan Lee, Chao-Kai Chou, Wen-Hao Yang, Yong-Kun Wei, Chun-Te Chen, Jun Yao, J. Hsu, Ci-Hui Zhu, Hao-Qiang Ying et al. · 2018 · Cancer Cell
The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis
Hongxuan Tong, Zhu Fan, Biyuan Liu, Tao Lu · 2018 · Scientific Reports
Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review
Durga S. Borkar, Mario E. Lacouture, Surendra Basti · 2012 · Supportive Care in Cancer
Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma
Jonathan Robert Brody, Christina L. Costantino, Magdalena Potoczek, Joseph A. Cozzitorto, Peter A. McCue, Charles J. Yeo, Ralph H. Hruban, Agnieszka Katarzyna Witkiewicz · 2009 · Modern Pathology
Treatment for Patients With Unknown Primary Carcinoma and Unfavorable Prognostic Factors
F. Anthony Greco, Nicholas A. Pavlidis · 2009 · Seminars in Oncology
Comparative analysis of traditional and coiled fiducials implanted during EUS for pancreatic cancer patients receiving stereotactic body radiation therapy
Mouen A. Khashab, Katherine J. Kim, Erik J. Tryggestad, Aaron Tyler Wild, Teboh Roland, Vikesh K. Singh, Anne Marie Lennon, Eun Ji Shin, Mark A. Ziegler, Reem Z. Sharaiha et al. · 2012 · Gastrointestinal Endoscopy
Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
Mario E. Lacouture, Dirk Schadendorf, Chia‐Yu Chu, Martina Uttenreuther‐Fischer, Uz M. Stammberger, Dennis O’Brien, Axel Hauschild · 2013 · Expert Review of Anticancer Therapy
Progress in the knowledge and treatment of advanced pancreatic cancer: From benchside to bedside
Helmut Oettle · 2014 · Cancer Treatment Reviews
Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy
Yongqing Qin, Shisong Han, Yahan Yu, Qi Ding, Mengnan Ran, Mingqi Yang, Yanyan Liu, Yunyi Li, Ligong Lu, Yu Liu et al. · 2024 · Liver International
Pancreatic cancer: Current and future treatment strategies
Kyriaki Pliarchopoulou, Dimitris Pectasides · 2009 · Cancer Treatment Reviews
Randomized Phase II Trials: A Long-term Investment With Promising Returns
Manish R. Sharma, Walter Michael Stadler, Mark J. Ratain · 2011 · JNCI Journal of the National Cancer Institute
Phase 2, multicenter, open‐label study of tigatuzumab (CS‐1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy‐naive patients with unresectable or metastatic pancreatic cancer
Andres Forero, Jeffrey R. Infante, David Michael Waterhouse, Lucas Wong, Selwyn Maurice Vickers, Edward R. Arrowsmith, Aiwu Ruth He, Lowell L. Hart, David F. Trent, James Lloyd Wade et al. · 2013 · Cancer Medicine
Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens
Lucia C. Petito, Xabier García‐Albéniz, Roger W Logan, Nadia Howlader, Angela B. Mariotto, Issa J Dahabreh, Miguel Ángel Hernán · 2020 · JAMA Network Open
Systemic Therapy for Metastatic Pancreatic Cancer
Thomas Jens Ettrich, Thomas Theodor Werner Seufferlein · 2021 · Current Treatment Options in Oncology
Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment
Steve Robatel, Mirjam Schenk · 2022 · Cancers
Coordinated Epidermal Growth Factor Receptor Pathway Gene Overexpression Predicts Epidermal Growth Factor Receptor Inhibitor Sensitivity in Pancreatic Cancer
Antonio Jimeno, Aik Choon Tan, Jordy Coffa, N.V. Rajeshkumar, Peter Kulesza, Belén Rubio‐Viqueira, Jenna Wheelhouse, Begoña Diosdado, Wells A. Messersmith, Christine A. Iacobuzio–Donahue et al. · 2008 · Cancer Research
Genetics of familial and sporadic pancreatic cancer
Wood, Laura D., Yurgelun, Matthew B., Goggins, Michael G. · 2019 · Gastroenterology
Sensitization of Pancreatic Cancer Stem Cells to Gemcitabine by Chk1 Inhibition
Venkatasubbaiah A. Venkatesha, Leslie A. Parsels, Joshua D. Parsels, Lili Zhao, Sonya Zabludoff, Diane M. Simeone, Jonathan Maybaum, Theodore Steven Lawrence, Meredith Ann Morgan · 2012 · Neoplasia
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours
Jeffrey R. Infante, Kyriakos P. Papadopoulos, Johanna C. Bendell, Amita Patnaik, Howard A. Burris, Drew Warren Rasco, Suzanne Fields Jones, Lon S. Smith, Donna S. Cox, M. Durante et al. · 2013 · European Journal of Cancer
Pancreatic cancer: from molecular pathogenesis to targeted therapy
Alexios S Strimpakos, Muhammad Wasif Saif, Kostas Syrigos · 2008 · Cancer and Metastasis Reviews
A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine
Tudor–Eliade Ciuleanu, Alexander V. Pavlovsky, Gyorgy Bodoky, Avgust M. Garin, Virginia K. Langmuir, S. Kroll, George F. Tidmarsh · 2009 · European Journal of Cancer
Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians
Rosella Spadi · 2016 · World Journal of Clinical Oncology
Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF 1‐dependent pathway
Ke Chen, Weikun Qian, Jie Li, Zhengdong Jiang, Liang Cheng, Bin Yan, Junyu Cao, Liankang Sun, Cancan Zhou, Meng Lei et al. · 2017 · Molecular Oncology
Current Immunotherapeutic Approaches in Pancreatic Cancer
Shigeo Koido, Sadamu Homma, Akitaka Takahara, Yoshihisa Namiki, Shintaro Tsukinaga, Jimi Mitobe, Shunichi Odahara, Toyokazu Yukawa, Hiroshi Matsudaira, Keisuke Nagatsuma et al. · 2011 · Clinical and Developmental Immunology
Combination Treatment With Comprehensive Cryoablation and Immunotherapy in Metastatic Pancreatic Cancer
Lizhi Niu, Jibing Chen, Lihua He, Mengtian Liao, Yuanying Yuan, Jianying Zeng, Jialiang Li, Jiansheng Zuo, Kecheng Xu · 2013 · Pancreas
Listeria delivers tetanus toxoid protein to pancreatic tumors and induces cancer cell death in mice
Benson Chellakkan Selvanesan, Dinesh Chandra, Wilber Quispe‐Tintaya, Arthee Jahangir, Ankur S. Patel, Kiran Meena, Rodrigo Alberto Alves da Silva, Madeline Friedman, Lisa R. Gabor, Olivia R Khouri et al. · 2022 · Science Translational Medicine
FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study
Alberto Zaniboni, Enrico Aitini, Sandro Barni, Daris Ferrari, Stefano Cascinu, Vincenzo Catalano, Giuseppe Valmadre, Domenica Ferrara, Enzo Maria Veltri, Claudio Codignola et al. · 2012 · Cancer Chemotherapy and Pharmacology
Current therapies and advances in the treatment of pancreatic cancer
Andrea Petricca Mancuso, Fabio Calabrò, Cora Nanette Sternberg · 2006 · Critical Reviews in Oncology/Hematology
Gemcitabine‐based combinations for inoperable pancreatic cancer: Have we made real progress?
Emilio Bria, Michèle Milella, Alain Jonathan Gelibter, Federica Cuppone, Maria Simona Pino, Enzo Maria Ruggeri, Paolo Carlini, Cecilia Nisticò, Edmondo Terzoli, Francesco Cognetti et al. · 2007 · Cancer
Kinases as targets in the treatment of solid tumors
Georgios Giamas, Yik L Man, Heidrun Hirner, Joachim Bischof, Klaus Michael Kramer, Kalimullah Khan, Sharmeen S. Lavina Ahmed, Justin Stebbing, Uwe Knippschild · 2010 · Cellular Signalling
Phase II Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients with Advanced Pancreatic Cancer
Muhammad Wasif Saif, Nikolai Alexandrovich Podoltsev, Mark S. Rubin, José A. Figueroa, Minyoung Y. Lee, Jin-Won Kwon, Elin Rowen, Jae-Won Yu, Robert O. Kerr · 2009 · Cancer Investigation
The clinical significance of SWI/SNF complex in pancreatic cancer
Masakatsu Numata, Soichiro Morinaga, Takuo Watanabe, Hiroshi Tamagawa, Naoto Yamamoto, Manabu Shiozawa, Yoshiyasu Nakamura, Yoichi Kameda, Shinichi Okawa, Yasushi Rino et al. · 2012 · International Journal of Oncology
PANVAC™-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma
Ravi Amrit Madan, Philip Martin Arlen, James L. Gulley · 2007 · Expert Opinion on Biological Therapy
Pancreatic Neoplasm in 2011: An Update
Muhammad Wasif Saif · 2015 · PubMed
Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline
John R. Goffin, Kevin M. Zbuk · 2013 · Clinical Therapeutics
Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer
Hayashi, Hideyuki, Kohno, Takashi, Ueno, Hideki, Hiraoka, Nobuyoshi, Kondo, Shunsuke, Saito, Motonobu, Shimada, Yoko, Ichikawa, Hitoshi, Kato, Mamoru, Shibata, Tatsuhiro et al. · 2017 · Pancreas
Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer
Yosuke Togashi, Akihiro Kogita, Hiroki Sakamoto, Hidetoshi Hayashi, Masato Terashima, Marco Antonio De Velasco, Kazuko Sakai, Yoshihiko Fujita, Shuta Tomida, Masayuki Kitano et al. · 2014 · Cancer Letters
HMGA1 Is a Molecular Determinant of Chemoresistance to Gemcitabine in Pancreatic Adenocarcinoma
Siong‐Seng Liau, Edward E. Whang · 2008 · Clinical Cancer Research
MicroRNA Expression as a Predictive Marker for Gemcitabine Response after Surgical Resection of Pancreatic Cancer
Kenoki Ohuchida, Kazuhiro Mizumoto, Tadashi Kayashima, Hayato Fujita, Taiki Moriyama, Takao Ohtsuka, Junji Ueda, Eishi Nagai, Makoto Hashizume, Masao Tanaka · 2011 · Annals of Surgical Oncology
Oncogenic K-Ras Signals through Epidermal Growth Factor Receptor and Wild-Type H-Ras to Promote Radiation Survival in Pancreatic and Colorectal Carcinoma Cells
Keith A. Cengel, K. Rahn Voong, Sanjay Chandrasekaran, Laurence Maggiorella, Thomas Baptist Brunner, Eric J. Stanbridge, Gary D. Kao, William Gillies McKenna, Eric J. Bernhard · 2007 · Neoplasia
Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors
Hofheinz, Ralf-Dieter, Deplanque, Gaël, Komatsu, Yoshito, Kobayashi, Yoshimitsu, Ocvirk, Janja, Racca, Patrizia, Guenther, Silke, Zhang, Jun, Lacouture, Mario E., Jatoi, Aminah · 2016 · The Oncologist